## Isabelle Castan-Laurell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2628518/publications.pdf

Version: 2024-02-01

		1040056	1372567	
10	1,166	9	10	
papers	citations	h-index	g-index	
10	10	10	1543	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Nuclear HMGB1 protects from nonalcoholic fatty liver disease through negative regulation of liver X receptor. Science Advances, 2022, 8, eabg9055.	10.3	7
2	SHP2 drives inflammation-triggered insulin resistance by reshaping tissue macrophage populations. Science Translational Medicine, $2021,13,.$	12.4	26
3	The apelin/APJ system as a therapeutic target in metabolic diseases. Expert Opinion on Therapeutic Targets, 2019, 23, 215-225.	3.4	39
4	Chronic apelin treatment improves hepatic lipid metabolism in obese and insulin-resistant mice by an indirect mechanism. Endocrine, 2018, 60, 112-121.	2.3	18
5	Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemicâ€euglycaemic clamp. Diabetes, Obesity and Metabolism, 2018, 20, 157-164.	4.4	42
6	Apelin and energy metabolism. Frontiers in Physiology, 2015, 6, 115.	2.8	158
7	Effects of Dietary Eicosapentaenoic Acid (EPA) Supplementation in High-Fat Fed Mice on Lipid Metabolism and Apelin/APJ System in Skeletal Muscle. PLoS ONE, 2013, 8, e78874.	2.5	46
8	Apelin Treatment Increases Complete Fatty Acid Oxidation, Mitochondrial Oxidative Capacity, and Biogenesis in Muscle of Insulin-Resistant Mice. Diabetes, 2012, 61, 310-320.	0.6	173
9	Apelin, diabetes, and obesity. Endocrine, 2011, 40, 1-9.	2.3	240
10	Apelin Stimulates Glucose Utilization in Normal and Obese Insulin-Resistant Mice. Cell Metabolism, 2008, 8, 437-445.	16.2	417